Institutional investors purchased a net $2.6 million shares of ALIM during the quarter ended June 2017 and now own 39.58% of the total shares outstanding. This is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
ARMISTICE CAPITAL LLC Bought 1.5 Million shares of Alimera Sciences Inc